Carlos Garcia Santos-Gallego

List of Publications by Year
in descending order

83 papers	3,119 citations	172207 29 h-index	168136 53 g-index
96 all docs	96 docs citations	96 times ranked	4292 citing authors

#	Article	IF	Citations
1	Not only how much, but also how to, when measuring epicardial adipose tissue. Magnetic Resonance Imaging, 2022, 86, 149-151.	1.0	7
2	Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102417.	1.8	29
3	Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. Journal of Cardiovascular Translational Research, 2022, 15, 944-956.	1.1	21
4	Perâ€Protocol Versus Intentionâ€toâ€Treat in Clinical Trials: The Example of GLOBALâ€LEADERS Trial. Journal of the American Heart Association, 2022, 11, e025561.	1.6	1
5	HDL: un nuevo biomarcador para la insuficiencia cardiaca. Revista Espanola De Cardiologia (English Ed) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	0
6	Randomized Trial of Empagliflozin in Nondiabetic Patients With HeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 243-255.	1.2	280
7	Reply: empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. Expert Review of Cardiovascular Therapy, 2021, 19, 101-102.	0.6	0
8	Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 393-407.	2.3	114
9	Overview of Aspirin and Platelet Biology. American Journal of Cardiology, 2021, 144, S2-S9.	0.7	22
10	In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status. Annals of Internal Medicine, 2021, 174, JC68.	2.0	4
11	Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF. JACC: Heart Failure, 2021, 9, 578-589.	1.9	118
12	Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	11
13	Â¿Son los inhibidores del receptor SGLT2 fÃ¡rmacos antidiabÃ©ticos o cardiovasculares?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 33-40.	0.4	2
14	Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. Expert Review of Cardiovascular Therapy, 2020, 18, 635-642.	0.6	7
15	Is Increased Cardiovascular and Bleeding Risk the Price for Pain Relief?. Journal of the American College of Cardiology, 2020, 76, 530-532.	1.2	2
16	Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis, 2020, 313, 76-80.	0.4	19
17	Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?. Journal of Cardiovascular Pharmacology, 2020, 75, 269-275.	0.8	3
18	Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma. Cardiovascular Research, 2020, 116, e93-e95.	1.8	6

#	Article	IF	Citations
19	Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. International Journal of Molecular Sciences, 2019, 20, 3289.	1.8	37
20	Reply. Journal of the American College of Cardiology, 2019, 74, 826.	1.2	2
21	Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the â€œCardiac Benefitsâ€• of Empagliflozin Independent of its Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2019, 33, 87-95.	1.3	51
22	Empagliflozin Ameliorates Adverse LeftÂVentricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 2019, 73, 1931-1944.	1.2	411
23	Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 275-285.	1.5	53
24	SGLT receptors and myocardial ischaemia-reperfusion injury: inhibition of SGLT-1, SGLT-2, or both?. Cardiovascular Research, 2019, 115, 1572-1573.	1.8	7
25	The anti-inflammatory effects of SGLT inhibitors. Aging, 2019, 11, 5866-5867.	1.4	15
26	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2018, 32, 213-222.	1.3	40
27	Echocardiographic and hemodynamic assessment for predicting early clinical events in severe acute mitral regurgitation. International Journal of Cardiovascular Imaging, 2018, 34, 171-175.	0.7	7
28	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1287-1302.	1.5	78
29	T2 magnetic resonance mapping: The key to find the â€˜Brahmastraâ€™ against atherosclerosis?. Atherosclerosis, 2018, 279, 95-96.	0.4	0
30	Spark That Lights the Fire: Infection Triggers Cardiovascular Events. Journal of the American Heart Association, 2018, 7, e011175.	1.6	3
31	High-Density Lipoproteinâ€"Targeted Therapiesâ€"Not Dead Yet. JAMA Cardiology, 2018, 3, 1254.	3.0	4
32	Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis. Methods in Molecular Biology, 2018, 1816, 161-171.	0.4	22
33	Modulatory Role of Pulsatility on vonÂWillebrand Factor. Journal of the American College of Cardiology, 2018, 71, 2119-2121.	1.2	10
34	MYOCARDIAL OXYGENATION USING BLOOD LEVEL-OXYGEN DEPENDENT SEQUENCE IN MAGNETIC RESONANCE DETERMINES MYOCARDIAL ENERGETICS AND CAPILLARY DENSITY. Journal of the American College of Cardiology, 2017, 69, 1439.	1.2	0
35	Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions. Atherosclerosis, 2017, 266, 81-86.	0.4	11
36	Non-cardiac sarcoid actually affects the heart by reducing coronary flow reserve. Atherosclerosis, 2017, 264, 74-76.	0.4	6

#	Article	IF	Citations
37	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. Journal of the American Heart Association, 2017, 6, .	1.6	13
38	Myocardial infarction caused by surgery: Blame inflammation not the surgeon. Atherosclerosis, 2016, 255, 113-116.	0.4	4
39	Niacin is still beneficial. Implications from an updated meta-regression analysis. Acta Cardiologica, 2016, 71, 463-472.	0.3	5
40	Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 67, 2032-2046.	1.2	62
41	MafB and the role of macrophage apoptosis in atherosclerosis: A time to kill, a time to heal. Atherosclerosis, 2016, 252, 194-196.	0.4	5
42	Cardiac Complications After Community-Acquired Pneumonia. American Journal of Cardiology, 2016, 117, 310.	0.7	8
43	Cadmium and atherosclerosis: Heavy metal or singing the blues?. Atherosclerosis, 2016, 249, 230-232.	0.4	19
44	Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion. Circulation, 2016, 133, 954-966.	1.6	155
45	Niacin is still beneficial. Implications from an updated meta-regression analysis. Acta Cardiologica, 2016, 71, 463-72.	0.3	2
46	DenervaciÃ³n renal por catÃ©ter como tratamiento para la hipertensiÃ³n pulmonar: Â¿esperanza o espejismo?. Revista Espanola De Cardiologia, 2015, 68, 551-553.	0.6	5
47	Catheter-based Renal Denervation as a Treatment for Pulmonary Hypertension: Hope or Hype?. Revista Espanola De Cardiologia (English Ed), 2015, 68, 551-553.	0.4	6
48	Reply to â€œLetter to the editor: Characterizing preclinical model of ischemic heart failure: difference between LAD and LCx infarctionsâ€• American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H365-H366.	1.5	1
49	Reply. Journal of the American College of Cardiology, 2015, 65, 1490-1491.	1.2	1
50	HDL Dysfunction. Journal of the American College of Cardiology, 2015, 66, 1486-1488.	1.2	15
51	Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition?. Haematologica, 2015, 100, 1103-1105.	1.7	5
52	Increased Stiffness Is the Major Early Abnormality in a Pig Model of Severe Aortic Stenosis and Predisposes to Congestive Heart Failure in the Absence of Systolic Dysfunction. Journal of the American Heart Association, 2015, 4, .	1.6	49
53	HDL: Quality or quantity?. Atherosclerosis, 2015, 243, 121-123.	0.4	50
54	Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctions. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1478-H1486.	1.5	43

#	Article	IF	Citations
55	Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 913-947.	1.2	85
56	Pathophysiology of Acute Coronary Syndrome. Current Atherosclerosis Reports, 2014, 16, 401.	2.0	217
57	The Sum of Two Evils. Journal of the American College of Cardiology, 2014, 64, 1926-1928.	1.2	39
58	Cardiac I-1c Overexpression With Reengineered AAV Improves Cardiac Function in Swine Ischemic Heart Failure. Molecular Therapy, 2014, 22, 2038-2045.	3.7	70
59	Role of HDL in Those with Diabetes. Current Cardiology Reports, 2014, 16, 512.	1.3	36
60	Role of HDL in those with diabetes. Current Cardiology Reports, 2014, 16, 512.	1.3	6
61	<i>SUMO-1</i> Gene Transfer Improves Cardiac Function in a Large-Animal Model of Heart Failure. Science Translational Medicine, 2013, 5, 211ra159.	5.8	96
62	Modelos experimentales de aterosclerosis. Revista Espanola De Cardiologia Suplementos, 2013, 13, 3-12.	0.2	3
63	Platelet function normalization after a prasugrel loadingâ€dose: timeâ€dependent effect of platelet supplementation. Journal of Thrombosis and Haemostasis, 2013, 11, 100-106.	1.9	48
64	VasculopatÃa del injerto cardiaco: la importancia de una nomenclatura estandarizada para la homogeneizaciÃ³n de estudios. Revista Colombiana De Cardiologia, 2013, 20, 111-113.	0.1	0
65	Ethnicity and cardiovascular riskâ€"are all men created equal?. Nature Reviews Cardiology, 2012, 9, 10-12.	6.1	2
66	Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type. Atherosclerosis, 2012, 220, 72-77.	0.4	95
67	High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities. Revista Espanola De Cardiologia (English Ed), 2012, 65, 305-308.	0.4	9
68	Papel de la proteÃna trasferidora de Ã©steres de colesterol en aterosclerosis: mÃ¡s preguntas que respuestas, mÃ¡s dudas que promesas. Revista Colombiana De Cardiologia, 2012, 19, 180-183.	0.1	0
69	LipoproteÃnas de alta densidad y reducciÃ³n de riesgo cardiovascular: Â¿promesas o realidades?. Revista Espanola De Cardiologia, 2012, 65, 305-308.	0.6	12
70	Free Mitral Regurgitation Due to Asynchrony and Improvement With Cardiac Resynchronization. Journal of the American College of Cardiology, 2012, 60, 232.	1.2	1
71	Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. Thrombosis and Haemostasis, 2012, 108, 1246-1248.	1.8	18
72	Adeno-associated Virus Serotype 8 ApoA-I Gene Transfer Reduces Progression of Atherosclerosis in ApoE-KO Mice: Comparison of Intramuscular and Intravenous Administration. Journal of Cardiovascular Pharmacology, 2011, 57, 325-333.	0.8	9

#	Article	IF	Citations
73	Experimental Models for the Investigation of High-Density Lipoproteinâ€"Mediated Cholesterol Efflux. Current Atherosclerosis Reports, 2011, 13, 266-276.	2.0	45
74	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidology, 2011, 6, 181-208.	0.4	9
75	Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 274-291.	0.4	51
76	Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. Atherosclerosis, 2009, 202, 185-191.	0.4	19
77	HDL-cholesterol: Is it really good?. Biochemical Pharmacology, 2008, 76, 443-452.	2.0	41
78	Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration. Journal of the American College of Cardiology, 2008, 51, 1104-1109.	1.2	122
79	TGF-Î²1: a novel target for cardiovascular pharmacology. Cytokine and Growth Factor Reviews, 2007, 18, 279-286.	3.2	38
80	P5-28. Heart Rhythm, 2006, 3, S269.	0.3	0
81	Pioglitazone Induces Vascular Smooth Muscle Cell Apoptosis Through a Peroxisome Proliferator-Activated Receptor-Â, Transforming Growth Factor-Â1, and a Smad2-Dependent Mechanism. Diabetes, 2005, 54, 811-817.	0.3	76
82	Enalapril prevents electrical and structural remodeling in a canine model of atrial fibrillation: Molecular mechanisms. Heart Rhythm, 2005, 2, S70.	0.3	1
83	Acetylsalicylic Acid Inhibits Cell Proliferation by Involving Transforming Growth Factor-Î². Circulation, 2003, 107, 626-629.	1.6	49